Redhill Biopharma (RDHL) Competitors $2.02 +0.02 (+0.75%) Closing price 07/3/2025 03:38 PM EasternExtended Trading$1.99 -0.03 (-1.24%) As of 07/3/2025 04:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock RDHL vs. LEXX, MRKR, PMN, CASI, HOTH, CLRB, CGTX, LPTX, BFRG, and XFORShould you be buying Redhill Biopharma stock or one of its competitors? The main competitors of Redhill Biopharma include Lexaria Bioscience (LEXX), Marker Therapeutics (MRKR), Promis Neurosciences (PMN), CASI Pharmaceuticals (CASI), Hoth Therapeutics (HOTH), Cellectar Biosciences (CLRB), Cognition Therapeutics (CGTX), Leap Therapeutics (LPTX), Bullfrog AI (BFRG), and X4 Pharmaceuticals (XFOR). These companies are all part of the "pharmaceutical products" industry. Redhill Biopharma vs. Its Competitors Lexaria Bioscience Marker Therapeutics Promis Neurosciences CASI Pharmaceuticals Hoth Therapeutics Cellectar Biosciences Cognition Therapeutics Leap Therapeutics Bullfrog AI X4 Pharmaceuticals Redhill Biopharma (NASDAQ:RDHL) and Lexaria Bioscience (NASDAQ:LEXX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, profitability, earnings, institutional ownership, valuation, dividends and risk. Which has more volatility & risk, RDHL or LEXX? Redhill Biopharma has a beta of 4.22, suggesting that its share price is 322% more volatile than the S&P 500. Comparatively, Lexaria Bioscience has a beta of 0.79, suggesting that its share price is 21% less volatile than the S&P 500. Do analysts recommend RDHL or LEXX? Lexaria Bioscience has a consensus price target of $5.00, indicating a potential upside of 458.66%. Given Lexaria Bioscience's stronger consensus rating and higher possible upside, analysts clearly believe Lexaria Bioscience is more favorable than Redhill Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Redhill Biopharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Lexaria Bioscience 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media favor RDHL or LEXX? In the previous week, Lexaria Bioscience had 8 more articles in the media than Redhill Biopharma. MarketBeat recorded 10 mentions for Lexaria Bioscience and 2 mentions for Redhill Biopharma. Redhill Biopharma's average media sentiment score of 0.00 beat Lexaria Bioscience's score of -0.17 indicating that Redhill Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Redhill Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Lexaria Bioscience 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Which has higher earnings and valuation, RDHL or LEXX? Lexaria Bioscience has lower revenue, but higher earnings than Redhill Biopharma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRedhill Biopharma$8.04M0.57-$8.27MN/AN/ALexaria Bioscience$460K34.17-$5.80M-$0.59-1.52 Do insiders and institutionals believe in RDHL or LEXX? 7.2% of Redhill Biopharma shares are owned by institutional investors. Comparatively, 13.1% of Lexaria Bioscience shares are owned by institutional investors. 6.8% of Redhill Biopharma shares are owned by insiders. Comparatively, 26.4% of Lexaria Bioscience shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Is RDHL or LEXX more profitable? Redhill Biopharma has a net margin of 0.00% compared to Lexaria Bioscience's net margin of -1,784.03%. Redhill Biopharma's return on equity of 0.00% beat Lexaria Bioscience's return on equity.Company Net Margins Return on Equity Return on Assets Redhill BiopharmaN/A N/A N/A Lexaria Bioscience -1,784.03%-111.84%-100.48% SummaryLexaria Bioscience beats Redhill Biopharma on 8 of the 14 factors compared between the two stocks. Get Redhill Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for RDHL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RDHL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RDHL vs. The Competition Export to ExcelMetricRedhill BiopharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.65M$2.43B$5.56B$9.04BDividend YieldN/A1.67%5.22%3.99%P/E RatioN/A9.3527.6620.25Price / Sales0.57687.54421.61119.11Price / CashN/A158.5936.8958.10Price / Book-0.554.588.035.67Net Income-$8.27M$31.34M$3.18B$249.21M7 Day Performance8.33%3.25%2.93%3.28%1 Month Performance1.26%3.46%1.72%3.95%1 Year Performance-99.10%0.77%34.39%20.98% Redhill Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RDHLRedhill BiopharmaN/A$2.02+0.8%N/A-99.1%$4.65M$8.04M0.00210LEXXLexaria Bioscience2.8531 of 5 stars$0.97+0.7%$7.00+623.8%-67.2%$16.86M$460K-1.647News CoverageUpcoming EarningsAnalyst ForecastAnalyst RevisionMRKRMarker Therapeutics3.2099 of 5 stars$1.42-2.1%$13.17+827.2%-68.3%$16.41M$6.59M-1.0760PMNPromis Neurosciences3.3942 of 5 stars$0.47-6.0%$4.50+857.2%-74.1%$16.34MN/A-9.405Gap UpCASICASI Pharmaceuticals4.1211 of 5 stars$1.23-7.2%$4.00+225.2%-76.8%$16.30M$28.54M-0.48180HOTHHoth Therapeutics1.4362 of 5 stars$1.23+1.2%$4.00+226.5%+38.5%$15.98MN/A-1.074Analyst UpgradeGap DownCLRBCellectar Biosciences3.3082 of 5 stars$0.30+2.1%$12.50+4,097.4%-93.3%$15.86MN/A-0.4110Gap UpHigh Trading VolumeCGTXCognition Therapeutics2.7911 of 5 stars$0.26+1.8%$5.63+2,067.6%-76.2%$15.81MN/A-0.3520News CoverageGap UpLPTXLeap Therapeutics1.4188 of 5 stars$0.31-18.0%$4.92+1,491.2%-85.6%$15.62MN/A-0.1840News CoverageHigh Trading VolumeBFRGBullfrog AI0.7272 of 5 stars$1.52-7.9%N/A+3.8%$15.54M$60K-1.884News CoverageXFORX4 Pharmaceuticals4.6695 of 5 stars$2.42-9.4%$72.33+2,889.0%-88.1%$15.46M$2.56M1.1380News CoverageHigh Trading Volume Related Companies and Tools Related Companies Lexaria Bioscience Competitors Marker Therapeutics Competitors Promis Neurosciences Competitors CASI Pharmaceuticals Competitors Hoth Therapeutics Competitors Cellectar Biosciences Competitors Cognition Therapeutics Competitors Leap Therapeutics Competitors Bullfrog AI Competitors X4 Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RDHL) was last updated on 7/6/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | Sponsored140% Yields From Stocks Like Tesla? Here's How (July 4th Special)Imagine getting a 140% dividend from your investments. Even better? It works with big names like Tesla, ...Investors Alley | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe day and month stocks are most likely to crash nextGood News for Stocks 50-year Wall Street veteran, Marc Chaikin is stepping forward to share why history giv...Chaikin Analytics | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Redhill Biopharma Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Redhill Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RDHL Stock Alerts